You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

~ Buy the APLENZIN (bupropion hydrobromide) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR APLENZIN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for APLENZIN

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00991081 ↗ Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial. Completed Johns Hopkins University Phase 4 2009-07-01 The major purpose of this exploratory developmental study will be to develop a patient-centered and feasible protocol for communicating genetic data as it relates to drug efficacy for smoking cessation inpatients receiving medication that is matched to individual genotypes associated with increased efficacy for bupropion or nicotine replacement therapy.
NCT00991081 ↗ Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial. Completed National Institute on Drug Abuse (NIDA) Phase 4 2009-07-01 The major purpose of this exploratory developmental study will be to develop a patient-centered and feasible protocol for communicating genetic data as it relates to drug efficacy for smoking cessation inpatients receiving medication that is matched to individual genotypes associated with increased efficacy for bupropion or nicotine replacement therapy.
NCT00991081 ↗ Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial. Completed SRI International Phase 4 2009-07-01 The major purpose of this exploratory developmental study will be to develop a patient-centered and feasible protocol for communicating genetic data as it relates to drug efficacy for smoking cessation inpatients receiving medication that is matched to individual genotypes associated with increased efficacy for bupropion or nicotine replacement therapy.
NCT00991081 ↗ Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial. Completed University of Bristol Phase 4 2009-07-01 The major purpose of this exploratory developmental study will be to develop a patient-centered and feasible protocol for communicating genetic data as it relates to drug efficacy for smoking cessation inpatients receiving medication that is matched to individual genotypes associated with increased efficacy for bupropion or nicotine replacement therapy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for APLENZIN

Condition Name

Condition Name for APLENZIN
Intervention Trials
Major Depressive Disorder 1
Smoking 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for APLENZIN
Intervention Trials
Depressive Disorder 1
Depression 1
Disease 1
Depressive Disorder, Major 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for APLENZIN

Trials by Country

Trials by Country for APLENZIN
Location Trials
United States 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for APLENZIN
Location Trials
New Jersey 1
Washington 1
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for APLENZIN

Clinical Trial Phase

Clinical Trial Phase for APLENZIN
Clinical Trial Phase Trials
Phase 4 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for APLENZIN
Clinical Trial Phase Trials
Completed 1
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for APLENZIN

Sponsor Name

Sponsor Name for APLENZIN
Sponsor Trials
Johns Hopkins University 1
National Institute on Drug Abuse (NIDA) 1
SRI International 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for APLENZIN
Sponsor Trials
Other 3
Industry 3
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.